Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Purchased by Leeward Investments LLC MA

Leeward Investments LLC MA increased its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 7.8% in the 4th quarter, HoldingsChannel reports. The firm owned 405,506 shares of the life sciences company’s stock after purchasing an additional 29,402 shares during the period. Leeward Investments LLC MA’s holdings in Integra LifeSciences were worth $9,197,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. KBC Group NV grew its stake in Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 1,120 shares in the last quarter. New York State Teachers Retirement System lifted its holdings in Integra LifeSciences by 3.0% during the 3rd quarter. New York State Teachers Retirement System now owns 90,098 shares of the life sciences company’s stock worth $1,637,000 after buying an additional 2,616 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after buying an additional 2,800 shares during the last quarter. Nordea Investment Management AB lifted its holdings in Integra LifeSciences by 4.1% during the 4th quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company’s stock worth $2,919,000 after buying an additional 5,032 shares during the last quarter. Finally, Choreo LLC lifted its holdings in Integra LifeSciences by 29.9% during the 4th quarter. Choreo LLC now owns 22,274 shares of the life sciences company’s stock worth $500,000 after buying an additional 5,123 shares during the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Stock Down 4.1 %

IART opened at $21.13 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The business has a 50 day moving average price of $23.71 and a two-hundred day moving average price of $21.81. Integra LifeSciences Holdings Co. has a 52 week low of $16.81 and a 52 week high of $45.11. The company has a market cap of $1.63 billion, a PE ratio of -234.75, a P/E/G ratio of 0.73 and a beta of 1.17.

Insiders Place Their Bets

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares in the company, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.10% of the stock is currently owned by insiders.

Analysts Set New Price Targets

IART has been the subject of a number of recent analyst reports. Citigroup lifted their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Morgan Stanley assumed coverage on Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 target price for the company. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.